RESEARCH ARTICLE

Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes: An analysis of the SEER database

Mingzhu Li¹*, Kai Chen²,³*, Fengtao Liu²,³*, Fengxi Su²,³, Shunrong Li²,³*, Liling Zhu²,³,⁴*

1 Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, China, 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China, 3 Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China, 4 Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, Connecticut, United States of America

☯ These authors contributed equally to this work.
* liling.zhu@yale.edu (LZ); lishr@mail.sysu.edu.cn (SL)

Abstract

Purpose

To determine the prevalence of nipple-sparing mastectomy (NSM) and its long-term survival outcomes in breast cancer patients.

Method

We used the Surveillance, Epidemiology, and End Results database and identified 2,440 breast cancer patients who received NSM during 1998–2013. We used chi-square and binary logistic regression to identify factors associated with the use of radiotherapy after NSM. We used Kaplan-Meier analysis to estimate cancer-specific survival (CSS) and overall survival (OS). We used the log-rank test and Cox regression to identify factors associated with CSS and OS.

Results

The median age of the population was 50 years. There were 725 (29.7%), 1064 (43.6%) and 651 (26.7%) patients who had Tis, T1 and T2-3 disease and 1943 (79.6%), 401 (16.4%) and 96 (3.9%) patients who had N0, N1 and N2-3 disease, respectively. The rates of RT use were 61.4%, 39.6% and 10.9% in patients with N2-3 disease, N1 or T3/N0 disease and Tis/T1-2/N0 disease, respectively. Elderly age, African American race, and higher T-stage and N-stage were associated with receiving radiotherapy. For patients diagnosed between 1998–2010 (N = 763), the median follow-up was 69 months. The 5- and 10-yr CSS were 96.9% and 94.9%, respectively. The 5- and 10-yr OS were 94.1% and 88.0%, respectively. Ethnicity, T-stage and N-stage were factors independently associated with CSS, and age and T-stage were factors independently associated with OS.
Conclusions
The use of NSM has increased, and it is oncologically safe for breast cancer patients.

Introduction
Nipple-sparing mastectomy (NSM) is a procedure that aims to preserve the nipple areolar complex and skin when performing a mastectomy to achieve better aesthetic outcomes after breast reconstruction. It is a popular surgical approach for patients receiving prophylactic mastectomy. Several studies[1–6] have reported the use of NSM as a therapeutic approach for breast cancer patients and its oncological outcomes. However, most of these studies were based on patients in a single institution and thus lacked sufficient generalizability. The National Comprehensive Cancer Network (NCCN) guidelines[7] state that NSM could be a surgical option in highly selected patients (e.g., those with a favorable prognosis)[7] and acknowledged that only retrospective studies were available as evidence. The nationwide patterns of NSM utilization in breast cancer patients and its associated long-term clinical outcomes remain unknown. The Surveillance, Epidemiology, and End Results (SEER) database is a national database covering one third of the cancer patients in the US. In this study, we aimed to use the SEER database to study 1) trends in the use of NSM between 1998 and 2013, 2) the long-term cancer-specific survival (CSS) and 3) the utilization of radiotherapy in this populations.

Methods
We searched the SEER registry data from 18 registries (Nov. 2015 submission) and included breast cancer patients who met all of the following inclusion criteria (S1 File).

Inclusion criteria
1. Female patients with pathological diagnosis of malignant disease of the breast. Carcinoma in situ patients were also included.
2. Patients who underwent nipple sparing mastectomy (code 30 in the SEER database)[8].
3. Patients diagnosed between 1990 and 2012.
4. Tis and T1-3 patients.

Exclusion criteria
1. Bilateral breast cancer patients.
2. Patients with previous diagnosis of any malignant tumors.
3. Patients with a phyllodes tumor of the breast.
4. Patients with inconsistent coding identified within the SEER database. For example, patients coded as carcinoma in situ and T2 or T3 were considered to have inconsistent coding.
Patients with unknown follow-up status.

This was an epidemiological study using de-identified data from the SEER registry. Ethical approval by the ethical committee of the Quanzhou First Hospital and Sun Yat-sen Memorial Hospital was waived based on our institutional policy. This study was reported based on the REMARK statements[9].

The following data were extracted for each patient: age, race, year of diagnosis, county type, marital status at diagnosis, grade, adjusted AJCC 6th T-stage, tumor size, primary site, histology subtype, estrogen receptor (ER) status, progesterone receptor (PR) status, radiation therapy (RT) use, survival month and SEER cause-specific death classification. Patients were categorized into three age groups based on their age at diagnosis (<50 yrs, 50–69 yrs, ≥70 yrs). Histology was divided into four categories (carcinoma in situ, infiltrating ductal carcinoma, lobular carcinoma and others).

Statistical analysis

A descriptive analysis of the patient characteristics was conducted. For survival analysis, the median follow-up was calculated as the median observed survival time of the entire population. To ensure the length of the follow-up to be sufficient, only patients from 1998–2010 were included in the survival analysis. Cancer-specific survival (CSS) and overall survival (OS) were measured as the time from diagnosis to breast cancer-related death and death due to any reasons, respectively. Cumulative CSS and OS were estimated using Kaplan-Meier analyses. We used the log-rank test to identify univariate risk factors for CSS and OS. We used the Cox proportional hazards regression to confirm risk factors independently associated with CSS and OS. We used Schoenfeld residuals to test the proportional-hazards assumptions. All P-values were two-sided. P-values of less than 0.05 were as considered statistically significant. Data were obtained using SEER*STAT 8.2.1. All data will be available upon request with a signed contract for data transfer agreement with the authors. The statistical analysis was performed using Stata/MP, version 13.0 (StataCorp LP, College Station, TX, USA) and R.

Results

Clinicopathological features

A total of 2,440 patients were included in this study (Table 1). Before 2009, less than 100 cases/year were coded as NSM in the SEER database. After 2009, the number of NSM increased rapidly, reaching 779 in 2013 (Fig 1). The median age of the entire population was 50 years. In total, 725 (29.7%), 1,064 (43.6%), 568 (23.3%) and 83 (3.4%) patients had Tis, T1, T2 and T3 disease, respectively. There were 1,943 (79.6%) patients with negative axillary nodes. There were 417 (17.1%) and 1,933 (79.2%) patients who did and did not receive RT, respectively. We also looked at the indications for RT in this cohort. Based on the indications for post-mastectomy RT provided by the NCCN guidelines, we categorized the patients into “RT recommended”, “RT considered” and “RT not recommended” cohorts, which consisted of patients with N2-3 disease, N1 or T3/N0 disease, and Tis/T1-2N0 disease, respectively (Table 2). In total, RT rates were 61.4%, 39.6% and 10.9% in the “RT recommended”, “RT considered” and “RT not recommended” cohorts, respectively. Over the entire study period, the RT rate fluctuated between 10–20% in the “RT not recommended” cohort. In the “RT considered” cohort, the rate of RT increased steadily between 2005 and 2013. In contrast, the rate of RT in the “RT recommended” cohort decreased from 80% during the 2001–2004 period to 60% during the 2001–2013 period.
Table 1. Clinicopathological features of included patients.

|                                | N   | %    |
|--------------------------------|-----|------|
| **Age Group**                  |     |      |
| <50                            | 1,165 | 47.75 |
| 50–69                          | 1,135 | 46.52 |
| >= 70                          | 140  | 5.74  |
| **Year Of Diagnosis**          |     |      |
| 1998–2002                      | 169  | 6.93  |
| 2003–2007                      | 242  | 9.92  |
| 2008–2013                      | 2,029 | 83.16 |
| **County Type 2003**           |     |      |
| Metropolitan                   | 2,253 | 92.34 |
| Non-Metropolitan               | 184  | 7.54  |
| Unknown                        | 3    | 0.12  |
| **Race**                       |     |      |
| White                          | 1,865 | 76.43 |
| African American               | 277  | 11.35 |
| Others                         | 275  | 11.27 |
| Unknown                        | 23   | 0.94  |
| **Marital Status**             |     |      |
| Married                        | 1,595 | 65.37 |
| Divorced/Separated/Single/Widowed | 770 | 31.56 |
| Unknown                        | 75   | 3.07  |
| **Primary Site**               |     |      |
| Nipple/Central Portion         | 113  | 4.63  |
| UIQ                            | 251  | 10.29 |
| LIQ                            | 140  | 5.74  |
| UOQ                            | 742  | 30.41 |
| LOQ                            | 226  | 9.26  |
| Overlapping/Unknown            | 500  | 20.49 |
| NOS                            | 468  | 19.18 |
| **T-Stage**                    |     |      |
| Tis                            | 725  | 29.71 |
| T1                             | 1,064 | 43.61 |
| T2                             | 568  | 23.28 |
| T3                             | 83   | 3.40  |
| **N-Stage**                    |     |      |
| N0                             | 1,943 | 79.63 |
| N1                             | 401  | 16.43 |
| N2                             | 69   | 2.83  |
| N3                             | 27   | 1.11  |
| **Histology**                  |     |      |
| In situ                        | 725  | 29.71 |
| IDC                            | 1,227 | 50.29 |
| ILC                            | 199  | 8.16  |
| Others                         | 289  | 11.84 |
| **Grade**                      |     |      |
| I                              | 415  | 17.01 |
| II                             | 998  | 40.90 |

(Continued)
Survival analysis

For the survival analyses, we included patients diagnosed between 1998–2010 as the study cohort (N = 763). With a median follow-up of 69 months, the 5- and 10-yr CSS rates were 96.9% and 94.9%, respectively. The 5- and 10-yr OS rates were 94.1% and 88.0%, respectively. Estimations of CSS and OS stratified by patient and tumor characteristics are summarized in Table 3. Univariate analysis using the log-rank test showed that race (P = 0.003), T-stage (P < 0.001), N-stage (P < 0.001), histology (P < 0.001) and RT status (P < 0.001) were significantly associated with CSS. Multivariate analysis (Table 4) showed that African American race (vs. White/others/Unknown, HR = 3.21, 95% CI 1.39–7.41) and higher T-stage (T1 vs. Tis, HR = 8.59, 95% CI 1.06–69.34; T2-3 vs. Tis, HR = 18.52, 95%CI 2.25–152.75) and N-stage (N1-3 vs. N0, HR = 2.41, 95% CI 1.06–5.48) were independent risk factors for CSS. For OS, age (P < 0.001), race (P = 0.010), marital status (P = 0.002), T-stage (P < 0.001), N-stage (P < 0.001), histology (P = 0.005) and RT status (P = 0.013) were significantly associated with OS. Multivariate analysis suggested that age (≥70yrs. Vs. <50yrs: HR = 4.81, 95%CI 2.46–9.40) and T-stage (T2-3 vs. Tis, HR = 2.78, 95%CI 1.32–5.84) were independent risk factors for OS. RT was not significant as an independent risk factor for CSS and OS.

Discussion

The registries of the SEER Program routinely collect data on patient demographic characteristics, clinicopathological features and vital status follow-up. The SEER database therefore serves as a reliable source of information for the investigation of the prevalence of and clinical outcomes associated with NSM. NSM performed was increased significantly after 2009. It is possible that patients receiving NSM were not appropriately coded as having undergone a NSM before 2009. Additionally, NSM was first used in the prophylactic settings, and therefore the numbers may actually be higher. Its use in breast cancer patients should be cautious and based on its oncological safety indicated by the published studies. We searched the Pubmed using

Table 1. (Continued)

|            | N   | %   |
|------------|-----|-----|
| III        | 766 | 31.39|
| IV         | 60  | 2.46 |
| Unknown    | 201 | 8.24 |
| ER         |     |     |
| Negative   | 336 | 13.77|
| Positive   | 1,862| 76.31|
| Unknown    | 242 | 9.92 |
| PR         |     |     |
| Negative   | 519 | 21.27|
| Positive   | 1,635| 67.01|
| Unknown    | 286 | 11.72|
| Radiation Therapy |   |     |
| No         | 1,933| 79.22|
| Yes        | 417 | 17.09|
| Unknown    | 90  | 3.69 |

ER, estrogen receptor; PR, progesterone receptor; LIQ, lower-inner quadrant; LOQ, lower-outer quadrant; UIQ, Upper-inner quadrant; UOQ, Upper-outer quadrant; NOS, Non otherwise specified. IDC, infiltrating ductal carcinoma; ILC, Invasive lobular carcinoma.

https://doi.org/10.1371/journal.pone.0183448.t001
the terms “Nipple sparing mastectomy breast cancer” in all fields and we observed that the number of identified publications had not been significantly increased until 2007-2009 (S1 Fig). This data suggested that the oncology community began to accept and embrace the NSM in breast cancer treatment after 2009.

Agarwal et al.[10] also studied the oncological safety of NSM in breast cancer treatment using data from the SEER database. However, their patient follow-up was relatively short. Only one- (100%) and 3-year CSS (97%) were reported. In our study population (N = 763), the 5- and 10-yr OS rates were 94.1% and 88.0% after a median follow-up of 69 months, respectively, suggesting the oncological safety of NSM in clinical practice. The CSS and OS of patients receiving NSM were, as expected, higher than those with non-NSM (total mastectomy or modified radical mastectomy) (S2 File). Selection bias plays a role in surgical decision making and patients who underwent a NSM likely had more favorable tumor characteristics. Similar OS (88–100%) of NSM have been observed in a series of retrospective studies[5,11–13] with

### Table 2. Temporal trends in the use of RT after NSM by NCCN recommendations.

| Year         | RT not recommended | RT considered | RT recommended |
|--------------|--------------------|---------------|----------------|
|              | %                  | Number of RT/ Total number | %                  | Number of RT/ Total number | %                  | Number of RT/ Total number |
| 1998–2000    | 23.73%             | (14/59)        | 28.57%          | (2/7)                        | 37.50%             | (3/8)                        |
| 2001–2004    | 15.60%             | (22/141)       | 25.81%          | (8/31)                       | 80.00%             | (4/5)                        |
| 2005–2007    | 9.45%              | (12/127)       | 27.27%          | (6/22)                       | 75.00%             | (3/4)                        |
| 2008–2010    | 18.56%             | (49/264)       | 38.98%          | (23/59)                      | 66.67%             | (10/15)                      |
| 2011–2013    | 8.24%              | (104/1262)     | 42.41%          | (123/290)                    | 60.71%             | (34/56)                      |

RT, Radiotherapy
Table 3. 5-year and 10-year cumulative CSS and OS of patients with different clinicopathological features.

| Age group    | Cancer-specific survival | Overall survival |
|--------------|--------------------------|------------------|
|              | 5-year       | 10-year       | Log-rank Test, P | 5-year       | 10-year       | Log-rank Test, P |
| <50          | 95.97        | 93.01         | NS              | 95.4         | 90.8          | <0.001          |
| 50–69        | 98.13        | 96.47         |                 | 95.69        | 88.86         |                |
| > = 70       | 95.69        | 95.69         |                 | 78.87        | 69.5          |                |
| County type 2003* |           |               |                 |              |               |                  |
| Metropolitan | 96.89        | 95.46         | NS              | 94.24        | 88.65         | NS              |
| Non-metropolitan | 96.97        | 90.93         |                 | 93.1         | 82.86         |                  |
| Race*        |             |               |                 |              |               |                  |
| White        | 97.63        | 95.18         | 0.003           | 95.08        | 88.38         | 0.01            |
| African American | 88.54        | 88.54         |                 | 82.94        | 79.48         |                  |
| Others       | 100          | 100           |                 | 98.48        | 94.55         |                  |
| Marital status* |             |               |                 |              |               |                  |
| Married      | 97.46        | 94.92         | NS              | 96.03        | 91.23         | 0.002           |
| Divorced     | 95.66        | 94.33         |                 | 90.35        | 82.33         |                  |
| Primary Site |             |               |                 |              |               |                  |
| Nipple/Central portion | 100        | 88.89         | NS              | 94.59        | 84.08         | NS              |
| UIQ          | 98.57        | 95.39         |                 | 97.14        | 94.01         |                 |
| LQ           | 94.5         | 94.5          |                 | 94.5         | 94.5          |                 |
| UOQ          | 97.24        | 94.46         |                 | 94.96        | 88.62         |                 |
| LOQ          | 100          | 94.44         |                 | 91.52        | 86.43         |                 |
| OVERLAPPING/UNKNOWN | 95.18       | 95.18         |                 | 92.67        | 86.47         |                 |
| NOS          | 96.62        | 96.62         |                 | 93.82        | 87.42         |                 |
| T-stage      |             |               |                 |              |               |                  |
| Tis          | 99.6         | 99.6          | <0.001          | 97.9         | 93.1          | <0.001          |
| T1           | 97.81        | 94.95         |                 | 96.11        | 89.6          |                 |
| T2           | 90.49        | 85.18         |                 | 84.92        | 75.87         |                 |
| T3           | 91.64        | 83.31         |                 | 84.28        | 76.62         |                 |
| N-stage      |             |               |                 |              |               |                  |
| N0           | 98.63        | 97.44         | <0.001          | 95.68        | 90.98         | <0.001          |
| N1           | 89.76        | 81.28         |                 | 88.96        | 72.71         |                 |
| N2           | 90.34        | 90.34         |                 | 86.04        | 76.48         |                 |
| N3           | 75           | 75            |                 | 68.18        | 68.18         |                 |
| Histology    |             |               |                 |              |               |                  |
| In situ carcinoma | 99.6         | 99.6          | <0.001          | 97.9         | 93.1          | 0.005           |
| IDC          | 93.94        | 91.26         |                 | 91.51        | 87.76         |                 |
| ILC          | 97.5         | 82.03         |                 | 95.73        | 69.73         |                 |
| Others       | 97.88        | 95.93         |                 | 90.64        | 82.23         |                 |
| Grade        |             |               |                 |              |               |                  |
| I            | 100          | 98.36         | NS              | 95.61        | 89.96         | NS              |
| II           | 97.24        | 93.66         |                 | 94.9         | 86.44         |                 |
| III          | 93.99        | 92.67         |                 | 92.17        | 88.75         |                 |
| IV           | 97.06        | 97.06         |                 | 92.14        | 83.32         |                 |
| Unknown      | 97.94        | 96.65         |                 | 94.78        | 90.57         |                 |

(Continued)
follow-ups > 5 years. There have been two studies[14,15] from European countries that have reported survival rates of less than 80% with similar follow-up durations. It is possible that the patients included in these two studies were diagnosed and treated between 1988 and 2000 and before the development of the concept of the “molecular subtype of breast cancer”[16] and respective treatment strategies. Cruz et al [17] conducted a systematic review and meta-analysis including 20 studies with 5594 patients. They compared the DFS and OS following NSM and modified radical mastectomy/skin sparing mastectomy and did not show any significant differences between the procedures. Taken together, our study was consistent with others and confirmed the long-term oncological safety of NSM in breast cancer patients.

Although these retrospective data support the oncological safety of NSM, we should be aware that patients were carefully selected for inclusion in these studies, with favorable biological features of the tumor (lower tumor grade, negative nodes, no lymphovascular invasion, etc.), as suggested by the NCCN guidelines[7]. However, it is still unknown what specific criteria defines patient eligibility or ineligibility for NSM. In this study, there were 26%, 20% and 13.8% of the NSM cases with T2-3, N1-3 and ER negative disease, respectively. Whether the clinical outcomes associated with NSM were due to its use in these patients is a major concern. In this study, the 10-year OS was 72% for N2-3 patients after NSM. This was significantly better than the reported outcomes following traditional mastectomy in patients with a similar tumor burden. In our previous study[18], we obtained data from the National Cancer Database and showed that the 8-year OS rates were 66.6% and 53.5% following traditional mastectomy in N2-3 patients with and without RT, respectively. Additionally, the 10-year OS rate for N1 patients in the current study was 72.7%; this result was comparable with the findings of a study using data from the Netherlands cancer registry[19], which showed that the 10-year OS rate ranged from 65 to 75% in T1-2N1 patients with a traditional mastectomy (with or without RT). Therefore, we suggest that tumor size (T2 vs. T1) or nodal status (N2-3, N1 vs. N0) may not be contraindications for NSM in breast cancer patients.

A lack of information regarding the rate of NAC positivity and local recurrence was one of the limitations of our study. The potential that malignant tumor cells remain in the preserved

Table 3. (Continued)

| Cancer-specific survival | Overall survival |
|--------------------------|-----------------|
| 5-year | 10-year | Log-rank Test, P | 5-year | 10-year | Log-rank Test, P |
|---|---|---|---|---|---|
| Negative | 92.39 | 92.39 | NS | 90.14 | 90.14 | NS |
| Positive | 97.29 | 94.5 | NS | 94.57 | 88.24 |
| Unknown | 97.7 | 96.64 | NS | 94.3 | 87.58 |
| PR | 94.27 | 93 | NS | 93.54 | 86.26 | NS |
| Positive | 97.02 | 94.17 | NS | 93.58 | 89.11 |
| Unknown | 97.95 | 96.91 | NS | 94.9 | 88.32 |
| Radiation therapy | | | | | | |
| No | 97.79 | 96.2 | <0.001 | 94.87 | 89.62 | 0.013 |
| Yes | 95.49 | 92.95 | NS | 92.85 | 83.87 |
| Unknown | 82.25 | 65.8 | NS | 82.25 | 65.8 |

ER, estrogen receptor; PR, progesterone receptor; LIQ, lower-inner quadrant; LOQ, lower-outer quadrant; UIQ, Upper-inner quadrant; UOQ, Upper-outer quadrant; NOS, Non otherwise specified.IDC, infiltrating ductal carcinoma; ILC, Invasive lobular carcinoma. NS, Non-significant; CSS, Cancer-specific survival; OS, Overall survival; * Patients with unknown status were excluded. Separated/Single/Widowed were included in the divorce category.

https://doi.org/10.1371/journal.pone.0183448.t003
nipple-areolar complex is a major concern regarding the oncological safety of NSM. Frozen section evaluation has been identified as an effective method to determine NAC status intraoperatively and thereby reduce the rate of NAC positivity. In a study by Eisenberg et al.[20], 325 patients received a frozen section evaluation of their NAC. The sensitivity and specificity were determined to be 64% and 99%, respectively. Alperovich et al.[21] performed a frozen section evaluation of the NAC of 307 cases receiving NSM and reported a sensitivity and specificity of 58% and 100%, respectively. Therefore, with the use of frozen section evaluation, half of cases with positive NAC margins can be identified intraoperatively. Even in institutions without frozen section evaluation, the rate of NAC positivity has been identified as 2.7–14%[6,20,22]. Re-excision or observation alone in these patients seems to be safe, although follow-up has been relatively short[6,22]. Petit et al.[23] reported that when combined with intraoperative radiotherapy, patients with a positive NAC margin identified during NSM may not need further treatment after surgery. Taken together, preserving the NAC during NSM might not compromise the local control of breast cancer in these patients. This was also confirmed in a meta-analysis reported by Cruz et al [17], which showed that the local recurrence risk was 0–11.7% in studies with longer than 5 years follow-up.

Post-mastectomy RT (PMRT) has been identified as an important adjuvant therapy for local control after surgery. The NCCN has clear recommendations regarding the indications for PMRT based on tumor size and nodal and margin status[7]. However, real-world clinical

### Table 4. Independent risk factors for CSS and OS in Cox proportional hazard regression analysis.

|                        | Cancer specific Survival | Overall Survival |
|------------------------|--------------------------|-----------------|
|                        | HR(95%CI) | P     | HR(95%CI) | P     |
| **Age**                |           |      |           |      |
| <50                    | Not included | 1     | 1.37(0.74–2.44) | 0.325 |
| 50–69                  |            |      | 4.81(2.46–9.40) | <0.001 |
| >= 70                  |            |      |           |      |
| **Marital***           |           |      |           |      |
| Married                | Not included | 1     | 1.55(0.92–2.61) | 0.099 |
| Divorced               |            |      |           |      |
| **Race**               |           |      |           |      |
| White/Others/Unknown   | 1.00       | 1    | 0.58(0.31–1.09) | 0.091 |
| African American       | 3.21(1.39–7.41) | 0.006 | 0.58(0.31–1.09) | 0.091 |
| **T-stage**            |           |      |           |      |
| Tis                    | 1.00       | 1    | 1.18(0.58–2.39) | 0.648 |
| T1                     | 8.59(1.06–69.34) | 0.044 | 2.78(1.32–5.84) | 0.007 |
| T2-3                   | 18.52(2.25–152.75) | 0.007 | 2.78(1.32–5.84) | 0.007 |
| **N-stage**            |           |      |           |      |
| NO                     | 1.00       | 1    | 1.57(0.85–2.89) | 0.149 |
| N1-3                   | 2.41(1.06–5.48) | 0.036 | 1.57(0.85–2.89) | 0.149 |
| **Radiotherapy**       |           |      |           |      |
| No                     | 1.00       | 1    | 1.02(0.43–2.42) | 0.962 |
| Yes                    | 3.86(1.24–12.01) | 0.020 | 2.26(0.79–6.43) | 0.126 |

Significant factors associated with CSS shown in univariate analysis (race, T-stage, N-stage and RT) were included in the Cox regression. Histology was excluded due to collinearity with T-stage. Univariate analysis suggested that African American patients had significantly lower CSS and OS than the other categories. Thus, we combined the "White", "Others" and "Unknown" categories as one category.

* Separated/Single/Widowed were included in the divorce category.

https://doi.org/10.1371/journal.pone.0183448.t004
practices in which more factors may be taken into consideration may not always follow these
guidelines. For example, concerns related to leaving remnants of ductal tissue with the NAC
may, theoretically, be more likely to prompt surgeons to recommend RT for NSM patients.
Frasier et al.[24] used the SEER database and reported that PMRT was delivered in 29.9% and
7.4% of the patients in which RT was and was not recommended by the NCCN guidelines,
respectively. Most of the reported studies[12,14,15,25] have shown that the rate of RT in NSM
patients ranged between 15 and 30%. However, most of these studies were retrospective, used
patients from a single institution, and did not provide detailed descriptions of the indications
for RT. Hence, it was unclear whether RT was more likely to be delivered in these patients. In
our study, the rates of RT were 61.4% (54/88) and 10.6% (201/1853) in the “RT recommended”
and “RT not recommended” cohorts, respectively, which were higher than the rate of RT iden-
tified in Frasier’s study[24]. Our results were consistent with Agarwal’s study[26] and showed
that NSM patients were more likely to receive RT than traditional mastectomy patients. How-
ever, whether PMRT in NSM patients is associated with improved local control and long-term
survival remains unclear. There has been only one study[14] that reported a significant differ-
ence in local or regional recurrence depending on the use of RT (RT: 8.5%, No RT: 28.4%).
However, several important factors, including tumor stage, were not adjusted for in that
study’s model. Additionally, a plate of gland tissue (5 mm) with a 2 cm diameter was left
around the NAC in their study, leading to a potentially higher risk of local or regional recur-
ces and, therefore, a potentially higher benefit of RT regarding local control. In our study,
we did not observe any benefit in CSS to be associated with RT, suggesting that RT can be
potentially avoided in more patients after NSM.

Several limitations of the SEER database should be noticed for accurate interpretation of
the results of our study. First, the SEER database did not have information about systemic ther-
apies, and therefore, their association with CSS in NSM patients cannot be assessed. Second,
some important clinicopathological features were not available in the SEER database, such as
tumor distance to nipple, Her2 status, margin status and lymphovascular invasion. Unable to
adjust these factors may have influences on the analysis of risk factors of CSS. Third, inappro-
priate coding, such as the underascertainment of the RT receipt[27], may exist in the SEER
database, which might bring bias to the study.

Summary

The use of NSM has been increasing, and these data suggest that this procedure is oncologi-
cally safe in breast cancer patients, even in the presence of a high tumor burden. The use of RT
after NSM identified in this study was also higher than that previously reported after tradi-
tional mastectomy. RT after NSM was associated with no benefit in terms of long-term sur-
vival. The role of RT after NSM in terms of local control remains unknown. We suggest that
the indications for PMRT after traditional mastectomy may be used as reliable references for
decision-making regarding the use of RT after NSM in breast cancer patients.

Supporting information

S1 Fig. Searched publications from Pubmed using “Nipple sparing mastectomy breast can-
cer” as terms in all fields.
(PNG)

S1 File. Coding for patient selection in the SEER database.
(DOCX)
S2 File. Comparison of CSS and OS in patients receiving NSM and non-NSM using the SEER database.

(DOCX)

Acknowledgments

The authors have no conflicts of interest or financial disclosures. This study was supported by the National Natural Science Foundation of China (Grant# 81402201/81372817), National Natural Science Foundation of Guangdong Province (Grant# 2014A030310070), and Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology.

Author Contributions

Conceptualization: ML KC LZ.
Data curation: KC LZ.
Formal analysis: FL FS ML.
Funding acquisition: KC FS.
Investigation: ML KC SL LZ.
Methodology: FL SL.
Project administration: SL LZ.
Resources: LZ.
Software: ML.
Supervision: LZ.
Validation: KC ML.
Writing – original draft: KC ML LZ.
Writing – review & editing: FS FL SL.

References

1. Adam H, Bygdeson M, de Boniface J (2014) The oncological safety of nipple-sparing mastectomy—a Swedish matched cohort study. Eur J Surg Oncol 40: 1209–1215. https://doi.org/10.1016/j.ejso.2014.07.037 PMID: 25186915
2. Moo TA, Pinchinat T, Mays S, Landers A, Christos P, Alabdulkareem H, et al. (2016) Oncologic Outcomes After Nipple-Sparing Mastectomy. Ann Surg Oncol 23: 3221–3225. https://doi.org/10.1245/s10434-016-5366-1 PMID: 27380643
3. Munhoz AM, Aldrighi CM, Montag E, Arruda EG, Aldrighi JM, Gemperli R, et al. (2013) Clinical outcomes following nipple-areola-sparing mastectomy with immediate implant-based breast reconstruction: a 12-year experience with an analysis of patient and breast-related factors for complications. Breast Cancer Res Treat 140: 545–555. https://doi.org/10.1007/s10549-013-2634-7 PMID: 23897416
4. Poruk KE, Ying J, Chidester JR, Olson JR, Matsen CB, Neumayer L, et al. (2015) Breast cancer recurrence after nipple-sparing mastectomy: one institution’s experience. Am J Surg 209: 212–217. https://doi.org/10.1016/j.amjsurg.2014.04.001 PMID: 24946727
5. Sakurai T, Zhang N, Suzuma T, Umemura T, Yoshimura G, Sakurai T, et al. (2013) Long-term follow-up of nipple-sparing mastectomy without radiotherapy: a single center study at a Japanese institution. Med Oncol 30: 481. https://doi.org/10.1007/s12032-013-0481-3 PMID: 23377926
6. Tang R, Coopey SB, Merrill AL, Rai U, Specht MC, Gadd MA, et al. (2016) Positive Nipple Margins in Nipple-Sparing Mastectomies: Rates, Management, and Oncologic Safety. J Am Coll Surg 222: 1149–1155. https://doi.org/10.1016/j.jamcol.surg.2016.02.016 PMID: 27118712

7. NCCN.org (2016) NCCN. Version I: 1–184.

8. Macmillan RD, Purushotham AD, Mallon E, Ramsay G, George WD (1994) Breast-conserving surgery and tumour bed positivity in patients with breast cancer. Br J Surg 81: 56–58. PMID: 8313122

9. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180–1184. https://doi.org/10.1093/jnci/dij237 PMID: 16106022

10. Agarwal S, Agarwal S, Neumayer L, Agarwal JP (2014) Therapeutic nipple-sparing mastectomy: trends based on a national cancer database. Am J Surg 208: 93–98. https://doi.org/10.1016/j.amjsurg.2013.09.030 PMID: 24581994

11. Caruso F, Ferrara M, Castiglione G, Trombetta G, De Meo L, Catanuto G, et al. (2006) Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol 32: 937–940. https://doi.org/10.1016/j.ejso.2006.05.013 PMID: 16829015

12. Jensen JA, Orringer JS, Giuliano AE (2011) Nipple-sparing mastectomy in 99 patients with a mean follow-up of 5 years. Ann Surg Oncol 18: 1665–1670. https://doi.org/10.1245/s10434-010-1475-4 PMID: 21174155

13. Shi A, Wu D, Li X, Zhang S, Li S, Xu H, et al. (2012) Subcutaneous Nipple-Sparing Mastectomy and Immediate Breast Reconstruction. Breast Care (Basel) 7: 131–136.

14. Benediktsson KP, Perbeck L (2008) Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol 34: 143–148. https://doi.org/10.1016/j.ejso.2007.06.010 PMID: 17709228

15. Gerber B, Krause A, Dieterich M, Kundt G, Reimer T (2009) The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 249: 461–468. https://doi.org/10.1097/SLA.0b013e31819a044f PMID: 19247035

16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752. https://doi.org/10.1038/35021093 PMID: 10963602

17. De La Cruz L, Moody AM, Tappy EE, Blankenship SA, Hecht EM (2015) Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann Surg Oncol 22: 3241–3249. https://doi.org/10.1245/s10434-015-4739-1 PMID: 2624363

18. Chen K, Liu J, Zhu L, Su F, Song E, Jacobs LK (2015) Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: A NCDB analysis. Oncotarget 6: 40127–40140. https://doi.org/10.18632/oncotarget.5394 PMID: 26517676

19. van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. (2016) 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 17: 1158–1170. https://doi.org/10.1016/S1470-2045(16)30067-5 PMID: 27344114

20. Eisenberg RE, Chan JS, Swistel AJ, Hoda SA (2014) Pathological evaluation of nipple-sparing mastectomies with emphasis on occult nipple involvement: the Weill-Cornell experience with 325 cases. Breast J 20: 15–21. https://doi.org/10.1111/tbj.12199 PMID: 24438063

21. Alperovich M, Choi M, Karp NS, Singh B, Ayo D, Frey JD, et al. (2016) Nipple-sparing Mastectomy and Sub-areolar Biopsy: To Freeze or not to Freeze? Evaluating the Role of Sub-areolar Intraoperative Frozen Section. Breast J 22: 18–23. https://doi.org/10.1111/tbj.12517 PMID: 26510917

22. Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman LJ (2015) Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management. Ann Surg Oncol 22: 3803–3808. https://doi.org/10.1245/s10434-015-4646-5 PMID: 26023040

23. Petit JY, Veronesi U, Orecchia R, Rey P, Martella S, Didier F, et al. (2009) Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat 117: 333–338. https://doi.org/10.1007/s10549-008-0304-y PMID: 19152026

24. Frasier LL, Holden S, Holden T, Schumacher JR, Leveon G, Anderson B, et al. (2016) Temporal Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With Changes in National Comprehensive Cancer Network Guidelines. JAMA Oncol 2: 95–101. https://doi.org/10.1001/jamaoncol.2015.3717 PMID: 26539936
25. Voltura AM, Tsangaris TN, Rosson GD, Jacobs LK, Flores JI, Singh NK, et al. (2008) Nipple-sparing mastectomy: critical assessment of 51 procedures and implications for selection criteria. Ann Surg Oncol 15: 3396–3401. https://doi.org/10.1245/s10434-008-0102-0 PMID: 18923874

26. Agarwal S, Agarwal J (2015) Radiation delivery in patients undergoing therapeutic nipple-sparing mastectomy. Ann Surg Oncol 22: 46–51. https://doi.org/10.1245/s10434-014-3932-y PMID: 25037972

27. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ (2012) Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer 118: 333–341. https://doi.org/10.1002/cncr.26295 PMID: 21717446